Another huge biotech deal could be in the making. Johnson & Johnson (NYSE: JNJ) wants to buy Swiss biotech Actelion Pharmaceuticals (NASDAQOTH: ALIOF). According to the Financial Times, however, Actelion is playing hard to get and prefers a partnership rather than acquisition. But would a potential buyout or more complicated combination be good for J&J shareholders?
Image source: Getty Images.